Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027627 (
metastases
)
103,950
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The molecular prognostic markers of metastasis are important for personalized approaches to clear cell renal cell carcinoma (ccRCC) treatment but markers for practical use are still missing. To address this gap we studied the expression of ten genes-
CA9
,
NDUFA4L2
,
VWF
,
IGFBP3
,
BHLHE41
,
EGLN3
,
SAA1
,
CSF1R
,
C1QA
, and FN1-through RT-PCR, in 56 ccRCC patients without
metastases
and with
metastases
. All of these, excluding
CSF1R
, showed differential and increased (besides
SAA1
) expression in non-metastasis tumors. The gene expression levels in metastasis tumors were decreased, besides
CSF1R
,
FN1
(not changed), and
SAA1
(increased). There were significant associations of the differentially expressed genes with ccRCC metastasis by ROC analysis and the Fisher exact test. The association of the
NDUFA4L2
,
VWF
,
EGLN3
,
SAA1
, and
C1QA
expression with ccRCC metastasis is shown for the first time. The
CA9
,
NDUFA4L2
,
BHLHE4
, and
EGLN3
were distinguished as the strongest candidates for ccRCC metastasis biomarkers. We used an approach that presupposed that the metastasis marker was the expression levels of any three genes from the selected panel and received sensitivity (88%) and specificity (73%) levels with a relative risk of RR > 3. In conclusion, a panel of selected genes-the candidates in biomarkers of ccRCC metastasis-was created for the first time. The results might shed some light on the ccRCC metastasis processes.
...
PMID:The Genes-Candidates for Prognostic Markers of Metastasis by Expression Level in Clear Cell Renal Cell Cancer. 3193 74